This article first appeared on GuruFocus .
Release Date: November 04, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Niagen Bioscience Inc ( NASDAQ:NAGE ) generated positive operating cash flow of $2.6 million and adjusted EBITDA of $450,000 in Q3 2026, demonstrating financial resilience.
-
The company ended the quarter with a strong balance sheet: $69.5 million in cash, no debt, and $83.3 million in working capital.
-
Direct-to-consumer website sales grew 13% year-over-year (17% adjusted for Prime Day timing), showing increasing demand for TrueNiagen.
-
Niagen Bioscience Inc ( NASDAQ:NAGE ) expanded distribution to Walmart.com, nearly 300 GNC locations, and Sam's Club across 44 states, enhancing brand accessibility.
-
The pharmaceutical program advanced with IND-enabling studies for NB4168 underway, and first-in-human studies planned for 2027, targeting rare diseases with potential high-value opportunities.
Negative Points
-
Net sales decreased 10% year-over-year to $27.2 million, with TrueNiagen contributing $23.3 million, due to timing of orders and increased competition.
-
Gross margin declined 160 basis points to 62.9% from 64.5% a year ago, reflecting unfavorable changes in product and business mix.
-
Selling and marketing expense as a percentage of net sales rose to 32% from 25.8%, driven by investments in brand awareness and new product launches.
-
General and administrative expense increased by $1.1 million to $8.2 million, primarily due to higher legal expenses from ongoing litigation.
-
Net loss was $1.2 million or $0.01 per diluted share, compared to net income of $0.06 per diluted share in the prior-year quarter, impacted by lower sales and higher costs.
Q & A Highlights
Q: Can you provide details on the Mass General Brigham prevention trial, including the categories studied, patient count, and duration? A: CEO Rob Fried explained that the study with Professor Howard Sesso at Harvard will evaluate healthy aging biomarkers like biological clocks, measures of intrinsic capacity, frailty indices, and the incidence of diseases related to cognitive function, cardiovascular health, and diabetes. The current plan is for approximately 5,000 participants over a three-year term, but he expects it to grow larger and potentially extend further, especially if other large entities join and a second ingredient is added.
Q: What is the strategy for the new lower-cost NR salt form, and will it be used for both the ingredients and supplements businesses? A: CEO Rob Fried stated that the new malate salt form, for which they now own the patents, works well and is more cost-efficient. It will be made available to ingredient partners and eventually integrated into the TrueNiagen portfolio in certain territories. He expects it to reduce the cost of goods in 2027 and in a significant way after that.
Q: Can you discuss the potential for the NB4168 pharmaceutical program, including the timeline for IND-enabling studies and the possibility of separate financing? A: CEO Rob Fried confirmed the expectation to complete IND-enabling studies in 2027, possibly in the first half, and to begin first-in-human studies. He noted the asset is "bio superior" and that its economic upside is "extremely appealing," especially with rising values for rare disease priority review vouchers. He stated it is possible a joint venture or separate financing arrangement for NAD Pharmaceuticals could occur in 2027 to maximize shareholder value.
Q: What are the characteristics of the new Niagen at-home injection kit, and how does it compare to competing products? A: CEO Rob Fried described the new offering as a liquid-based vial in a syringe format, which is simpler than the previous powder vial that required reconstitution. He compared it to products in the peptide community, noting it is not yet a pen like in the GLP-1 space, but they are working on a pen that could be available in about a year. The focus is on a simpler product experience to drive adoption.
Q: Can you provide an update on the China cross-border business and its long-term potential? A: CFO Ozan Pamir stated that the China cross-border business is showing strength and is expected to be more than two to three times larger compared to last year. CEO Rob Fried added that while the cross-border business is growing, the "home run" opportunity is gaining Blue Hat approval to sell in mainland China, which could be a year away. He believes the mainland China market for TrueNiagen could be bigger than the U.S. market.
Q: What is the outlook for the skincare business, including the partnership with a large beauty player and the performance of your own NanoCloud product? A: CEO Rob Fried expressed high hopes for Niagen in skincare, citing a favorable independent study by Estee Lauder. He confirmed a topical product with a large global skincare company is expected in early 2027. Early sales of their own NanoCloud product have been "very strong," and it is expected to be available on Amazon within days. He hopes their own brands will eventually be bigger than the ingredient business.
Q: Regarding the elevated G&A expenses this quarter, was there anything unusual, and what is the expected trend? A: CFO Ozan Pamir attributed the higher G&A to litigation expenses, which were heavier in the quarter due to a specific period in the litigation requiring additional investment. He expects these costs to come down once the litigation is resolved and for G&A to return to more normal levels.
Q: Can you discuss the new ingredient partners added in Q3 and the outlook for additional partners? A: CFO Ozan Pamir stated that the new partners added in the quarter are a range of mostly international customers, including CMO customers. While they are starting out small, he has decent expectations for them and anticipates adding more partners in the near term.
Q: What is the status of the Sam's Club launch, and what is the strategy for other club channels like Costco? A: CEO Rob Fried confirmed they are offering one SKU at Sam's Club and are seeing early signs of strength. He expressed hope that this success will translate to other club channels like Costco in the future.
Q: Did the company defer any marketing costs from Q3 to Q4 related to the new brand campaign? A: CFO Ozan Pamir clarified that the brand campaign launched in October, so the creative work done in Q2 and Q3 will be recognized as expenses in Q4.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
